Nirsevimab Protects Infants Against RSV-Linked Hospitalization

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 28, 2023 -- Nirsevimab is efficacious for preventing hospitalization for respiratory syncytial virus (RSV)-associated lower respiratory tract infection among infants, according to a study published in the Dec. 28 issue of the New England Journal of Medicine.

Simon B. Drysdale, Ph.D., from the Centre for Neonatal and Paediatric Infections at the University of London, and colleagues conducted a pragmatic trial involving infants aged 12 months or younger, born at gestational age of at least 29 weeks who were entering their first RSV season in France, Germany, or the United Kingdom. The infants were randomly assigned to receive a single intramuscular injection of nirsevimab (4,037 infants) or standard care (no intervention; 4,021 infants) before or during the RSV season.

The researchers found that 0.3 and 1.5 percent of infants in the nirsevimab and standard-care groups, respectively, were hospitalized for RSV-associated lower respiratory tract infection, corresponding to 83.2 percent efficacy for nirsevimab. Very severe RSV-associated lower respiratory tract infection occurred in 0.1 and 0.5 percent of infants in the nirsevimab and standard-care groups, respectively, corresponding to 75.7 percent efficacy. In France, Germany, and the United Kingdom, the efficacy of nirsevimab against hospitalization for RSV-associated lower respiratory tract infection was 89.6, 74.2, and 83.4 percent, respectively. Overall, 2.1 percent of the nirsevimab group had treatment-related adverse events.

"These findings suggest that nirsevimab has the potential to reduce the burden of hospitalization for RSV-associated lower respiratory tract infection among infants," the authors write.

The study was funded by Sanofi and AstraZeneca, which manufacture nirsevimab.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-29 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords